Articles related to ACUTE CORONARY SYNDROME (ACS)

In a comprehensive Bayesian network meta-analysis, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a significant reduction in major bleeding compared to the conventional 12 months of DAPT, without an increase in MACCE.

In patients with chronic kidney disease, the elevated troponin challenge necessitates a nuanced approach, integrating serial measurements and clinical context to discern acute coronary syndrome from chronic elevations, thereby informing targeted management strategies.

Accelerate your understanding of thrombotic disease treatment developments; delve into the Fast Track designation of milvexian, a promising oral factor XIa inhibitor.

Most current guidelines recommend at least 12 months of dual anti-platelet therapy for ACS and post PCI. But is that the best approach in an aging population with inherent higher bleeding risk? Some are advocating very early cessation of aspirin as well as scaling down the P2Y12 inhibitor in the first few months post event.

This study involved 566 men and women between the ages of 28 and 97 years, who were patients in a preventive cardiology practice. The PULS Cardiac Test measures multiple protein biomarkers, including hepatocyte growth factor, soluble Fas, and IL-16, and uses the results to calculate a five-year risk score for new ACS. All factors more than doubled their prior above the norm level. The 5-year ACS PULS risk score more than doubled as a result.